Juliusson G, Hough R. Leukemia. Prog Tumor Res. 2016;43:87–100.
Kropp EM, Li Q. Mechanisms of resistance to focused therapies for relapsed or refractory acute myeloid leukemia. Exp Hematol. 2022;111:13–24.
Yang Z, Liu Y, Wang L, Lin S, Dai X, Yan H, Ge Z, Ren Q, Wang H, Zhu F, Wang S. Conventional chinese language medication in opposition to COVID-19: function of the intestine microbiota. Biomed Pharmacother. 2022;149:112787.
Zhai B, Zeng Y, Zeng Z, Zhang N, Li C, Zeng Y, You Y, Wang S, Chen X, Sui X, Xie T. Drug supply methods for elemene, its important energetic ingredient beta-elemene, and its derivatives in most cancers remedy. Int J Nanomedicine. 2018;13:6279–96.
Yao Y, Li F, Huang J, Jin J, Wang H. Leukemia stem cell-bone marrow microenvironment interaction in acute myeloid leukemia growth. Exp Hematol Oncol. 2021;10:39.
Tzogani Ok, Penttila Ok, Lapvetelainen T, Hemmings R, Koenig J, Freire J, Marcia S, Cole S, Coppola P, Flores B, et al. EMA Evaluation of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the therapy of adults with newly recognized, therapy-related Acute myeloid leukemia or Acute myeloid leukemia with myelodysplasia-related modifications. Oncologist. 2020;25:e1414–20.
Ci T, Zhang W, Qiao Y, Li H, Zang J, Li H, Feng N, Gu Z. Supply methods in remedies of leukemia. Chem Soc Rev. 2022;51:2121–44.
Rivankar S. An outline of doxorubicin formulations in most cancers remedy. J Most cancers Res Ther. 2014;10:853–8.
De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a complete evaluate and 2016 replace. Blood Most cancers J. 2016;6:e441.
Quick NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593–606.
Benjamin RS, Wiernik PH, Bachur NR. Adriamycin. Ann Intern Med. 1974;81:414–5.
Sagar S, Kaur M, Minneman KP. Antiviral lead compounds from marine sponges. Mar Medicine. 2010;8:2619–38.
Khokhlatchev AV, Sharma A, Deering TG, Shaw JJP, Costa-Pinheiro P, Golla U, Annageldiyev C, Cabot MC, Conaway MR, Tan SF, et al. Ceramide nanoliposomes increase the efficacy of venetoclax and cytarabine in fashions of acute myeloid leukemia. FASEB J. 2022;36:e22514.
Dinner SN, Giles FJ, Altman JK. New methods for relapsed acute myeloid leukemia: fertile floor for translational analysis. Curr Opin Hematol. 2014;21:79–86.
Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner Ok, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, et al. Remedy of acute myelocytic leukemia: a research by most cancers and leukemia group B. Blood. 1981;58:1203–12.
Baker WJ, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9:679–93.
Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline therapy of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017;110:20–34.
Dong T, Wu N, Gao H, Liang S, Dong X, Zhao T, Jiang Q, Liu J. CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia in direction of Vdelta2(+) T cell cytotoxicity. Ann Hematol. 2022;101:2195–208.
Almatani MF, Ali A, Onyemaechi S, Zhao Y, Gutierrez L, Vaikari VP, Alachkar H. Methods focusing on FLT3 past the kinase inhibitors. Pharmacol Ther. 2021;225:107844.
Enioutina EY, Salis ER, Job KM, Gubarev MI, Krepkova LV, Sherwin CM. Natural Medicines: challenges within the trendy world. Half 5. Standing and present instructions of complementary and various natural medication worldwide. Professional Rev Clin Pharmacol. 2017;10:327–38.
Wang Z, Liu X, Ho RL, Lam CW, Chow MS. Precision or Personalised Drugs for Most cancers Chemotherapy: is there a job for Natural Drugs. Molecules 2016, 21.
Zhang J, Li X, Huang L. Anticancer actions of phytoconstituents and their liposomal focusing on methods in opposition to tumor cells and the microenvironment. Adv Drug Deliv Rev. 2020;154–155:245–73.
Gezici S, Sekeroglu N. Present views within the utility of Medicinal crops in opposition to Most cancers: Novel Therapeutic Brokers. Anticancer Brokers Med Chem. 2019;19:101–11.
Swindell EP, Hankins PL, Chen H, Miodragovic DU, O’Halloran TV. Anticancer exercise of small-molecule and nanoparticulate arsenic(III) complexes. Inorg Chem. 2013;52:12292–304.
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Solar GL, Yang KQ, et al. Use of arsenic trioxide (As2O3) within the therapy of acute promyelocytic leukemia (APL): II. Medical efficacy and pharmacokinetics in relapsed sufferers. Blood. 1997;89:3354–60.
Selvakesavan RK, Franklin G. Potential utility of Nanoparticles Inexperienced Synthesized utilizing Medicinal Plant extracts as Novel Nanomedicines. Nanotechnol Sci Appl. 2021;14:179–95.
Chen Z, Hong G, Liu Z, Yang D, Kankala RK, Wu W. Synergistic antitumor efficacy of doxorubicin and gambogic acid-encapsulated albumin nanocomposites. Colloids Surf B Biointerfaces. 2020;196:111286.
Wang J, Wong YK, Liao F. What has conventional chinese language medication delivered for contemporary medication? Professional Rev Mol Med. 2018;20:e4.
Du M, Ouyang Y, Meng F, Ma Q, Liu H, Zhuang Y, Pang M, Cai T, Cai Y. Nanotargeted brokers: an rising therapeutic technique for breast most cancers. Nanomed (Lond). 2019;14:1771–86.
Chen Z, Hong G, Liu Z, Yang D, Kankala RK, Wu W. Synergistic antitumor efficacy of doxorubicin and gambogic acid-encapsulated albumin nanocomposites. Colloids Surf B. 2020;196:111286.
Wilson B, Mukundan Geetha Ok. Nanomedicine to ship organic macromolecules for treating COVID-19. Vaccine. 2022;40:3931–41.
Mohapatra P, Singh P, Sahoo SK. Phytonanomedicine: a novel avenue to deal with recurrent most cancers by focusing on most cancers stem cells. Drug Discov At present. 2020;25:1307–21.
Mago A, Junaid Tahir M, Arslan Khan M, Abbasher Hussien Mohamed Ahmed Ok, Usman Munir M. Nanomedicine: Development in healthcare. Ann Med Surg (Lond). 2022;79:104078.
Junghanns JU, Muller RH. Nanocrystal expertise, drug supply and scientific functions. Int J Nanomedicine. 2008;3:295–309.
Jarvis M, Krishnan V, Mitragotri S. Nanocrystals: a perspective on translational analysis and scientific research. Bioeng Transl Med. 2019;4:5–16.
Hanqing Y. Examine on antitumor mechanism of nano-realgar. Huazhong College of Science and Expertise; 2005.
Wu G-c, Zhang M, Wang Y-q, Mothibe KJ, Chen W. -x: manufacturing of silver carp bone powder utilizing superfine grinding expertise: appropriate manufacturing parameters and its properties. J Meals Eng. 2012;109:730–5.
Chuan W. Preparation of Realgar Aqueous dispersion formulation and research on antitumor efficacy. Beijing: Peking Union Medical School. 2017.
Dinshaw IJ, Ahmad N, Salim N, Leo BF. Nanoemulsions: A Evaluation on the Conceptualization of Remedy for Psoriasis Utilizing a ‘Inexperienced’ Surfactant with Low-Power Emulsification Methodology. Pharmaceutics. 2021;13(7):1024.
Liu L, Qi XJ, Zhong ZK, Zhang EN. Nanomedicine-based mixture of gambogic acid and retinoic acid chlorochalcone for enhanced anticancer efficacy in osteosarcoma. Biomed Pharmacother. 2016;83:79–84.
Ma Q, Wang C, Li X, Guo H, Meng J, Liu J, Xu H. Fabrication of water-soluble polymer-encapsulated As4S4 to extend oral bioavailability and chemotherapeutic efficacy in AML mice. Sci Rep. 2016;6:29348.
Wang T, Zhang X, Jia M, Yang A, Liu J, Wen T, Meng J, Xu H. Hydrophilic realgar nanocrystals delay the survival of Refractory Acute myeloid leukemia mice by way of inducing Multi-Lineage differentiation and apoptosis. Int J Nanomedicine. 2022;17:2191–202.
Feng Z, Wang Z, Yang Y, Du Y, Cui S, Zhang Y, Tong Y, Track Z, Zeng H, Zou Q, et al. Improvement of a security and efficacy nanoemulsion supply system encapsulated gambogic acid for acute myeloid leukemia in vitro and in vivo. Eur J Pharm Sci. 2018;125:172–80.
Li J, Yang L, Shen R, Gong L, Tian Z, Qiu H, Shi Z, Gao L, Solar H, Zhang G. Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia exercise of berberine. J Nanobiotechnol. 2018;16:76.
Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. Engineered nanocrystal expertise: in-vivo destiny, focusing on and functions in drug supply. J Management Launch. 2014;183:51–66.
Xu HY, Liu CS, Huang CL, Chen L, Zheng YR, Huang SH, Lengthy XY. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal problem. Colloids Surf B Biointerfaces. 2019;181:927–34.
Huang X, Lin H, Huang F, Xie Y, Wong KH, Chen X, Wu D, Lu A, Yang Z. Focusing on approaches of Nanomedicines in Acute myeloid leukemia. Dose Response. 2019;17:1559325819887048.
Houshmand M, Garello F, Circosta P, Stefania R, Aime S, Saglio G, Giachino C. Nanocarriers as magic bullets within the therapy of Leukemia. Nanomaterials (Basel). 2020;10(2):276.
Ahmad Z, Shah A, Siddiq M, Kraatz HB. Polymeric micelles as drug supply automobiles. RSC Adv. 2014;4:17028–38.
Bottger R, Pauli G, Chao PH, Al Fayez N, Hohenwarter L, Li SD. Lipid-based nanoparticle applied sciences for liver focusing on. Adv Drug Deliv Rev. 2020;154–155:79–101.
Yaghmur A, Mu H. Current advances in drug supply functions of cubosomes, hexosomes, and strong lipid nanoparticles. Acta Pharm Sin B. 2021;11:871–85.
Mei Z, Wu Q, Hu S, Li X, Yang X. Triptolide loaded strong lipid nanoparticle hydrogel for topical utility. Drug Dev Ind Pharm. 2005;31:161–8.
Dong X, Ma N, Liu M, Liu Z. Results of As(2)O(3) nanoparticles on cell progress and apoptosis of NB4 cells. Exp Ther Med. 2015;10:1271–6.
Chen M, Xiong F, Ma L, Yao H, Wang Q, Wen L, Wang Q, Gu N, Chen S. Inhibitory impact of magnetic Fe(3)O(4) nanoparticles coloaded with homoharringtonine on human leukemia cells in vivo and in vitro. Int J Nanomedicine. 2016;11:4413–22.
Deshpande PP, Biswas S, Torchilin VP. Present developments in the usage of liposomes for tumor focusing on. Nanomed (Lond). 2013;8:1509–28.
Chung JW, Guo Y, Priestley RD, Kwak SY. Colloidal gold nanoparticle formation derived from self-assembled supramolecular construction of cyclodextrin/Au salt complicated. Nanoscale. 2011;3:1766–72.
Li Y, Zhang R, Xu Z, Wang Z. Advances in Nanoliposomes for the analysis and therapy of Liver Most cancers. Int J Nanomedicine. 2022;17:909–25.
Chen H, MacDonald RC, Li S, Krett NL, Rosen ST, O’Halloran TV. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and permits for managed anticancer drug launch. J Am Chem Soc. 2006;128:13348–9.
Darwish NHE, Sudha T, Godugu Ok, Bharali DJ, Elbaz O, El-Ghaffar HAA, Azmy E, Anber N, Mousa SA. Novel focused Nano-Parthenolide molecule in opposition to NF-kB in Acute myeloid leukemia. Molecules 2019, 24.
Khosravani F, Mir H, Mirzaei A, Kobarfard F, Bardania H, Hosseini E. Arsenic trioxide and Erlotinib loaded in RGD-modified nanoliposomes for focused mixture supply to PC3 and PANC-1 cell strains. Biotechnol Appl Biochem. 2022;70(2):811–823.
Barth BM, Wang W, Toran PT, Fox TE, Annageldiyev C, Ondrasik RM, Keasey NR, Brown TJ, Devine VG, Sullivan EC, et al. Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. Blood Adv. 2019;3:2598–603.
Bose A, Roy Burman D, Sikdar B, Patra P. Nanomicelles: sorts, properties and functions in drug supply. IET Nanobiotechnol. 2021;15:19–27.
Trinh HM, Cholkar MJK, Mitra R. A.Ok. Mitra,: Nanomicelles in analysis and drug supply. Emerg Nanotechnologies Diagnostics Drug Supply Med Gadgets. 2017:45–8.
Ghosh B, Biswas S. Polymeric micelles in most cancers remedy: cutting-edge. J Management Launch. 2021;332:127–47.
Ghezzi M, Pescina S, Padula C, Santi P, Del Favero E, Cantu L, Nicoli S. Polymeric micelles in drug supply: an perception of the methods for his or her characterization and evaluation in biorelevant situations. J Management Launch. 2021;332:312–36.
Tima S, Anuchapreeda S, Ampasavate C, Berkland C, Okonogi S. Steady curcumin-loaded polymeric micellar formulation for enhancing mobile uptake and cytotoxicity to FLT3 overexpressing EoL-1 leukemic cells. Eur J Pharm Biopharm. 2017;114:57–68.
Trinh HM, Joseph M, Cholkar Ok, Mitra R, Mitra AK. Nanomicelles in Prognosis and Drug Supply. 2017:45–58.
Dahan A, Beig A, Lindley D, Miller JM. The solubility-permeability interaction and oral drug formulation design: two heads are higher than one. Adv Drug Deliv Rev. 2016;101:99–107.
Murakami T. Absorption websites of orally administered medication within the small gut. Professional Opin Drug Discov. 2017;12:1219–32.
Tima S, Ichikawa H, Ampasavate C, Okonogi S, Anuchapreeda S. Inhibitory impact of turmeric curcuminoids on FLT3 expression and cell cycle arrest within the FLT3-overexpressing EoL-1 leukemic cell line. J Nat Prod. 2014;77:948–54.
Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. Oral anticancer medication: mechanisms of low bioavailability and techniques for enchancment. Clin Pharmacokinet. 2013;52:399–414.
Baranello MP, Bauer L, Jordan CT, Benoit DSW. Micelle Supply of Parthenolide to Acute myeloid leukemia cells. Cell Mol Bioeng. 2015;8:455–70.
Sudha T, Bharali DJ, Yalcin M, Darwish NH, Coskun MD, Keating KA, Lin HY, Davis PJ, Mousa SA. Focused supply of cisplatin to tumor xenografts by way of the nanoparticle part of nano-diamino-tetrac. Nanomed (Lond). 2017;12:195–205.
Bonifacio BV, Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug supply methods and natural medicines: a evaluate. Int J Nanomedicine. 2014;9:1–15.
Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MdP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S et al. Nano primarily based drug supply methods: current developments and future prospects. J Nanobiotechnol. 2018;16.
Fan L, Liu C, Hu A, Liang J, Li F, Xiong Y, Mu CF. Twin oligopeptides modification mediates arsenic trioxide containing nanoparticles to remove primitive continual myeloid leukemia cells inside bone marrow niches. Int J Pharm. 2020;579:119179.
Chen C, Wang L, Li L, Wang A, Huang T, Hu J, Zhao M, Liu F, Qi S, Hu C, et al. Community-based evaluation with main cells reveals drug response panorama of acute myeloid leukemia. Exp Cell Res. 2020;393:112054.
Balasundaram N, Ganesan S, Chendamarai E, Palani HK, Venkatraman A, Alex AA, David S, Kumar SP, Radhakrishnan NR, Yasar M, et al. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood Adv. 2022;6:652–63.
Giri B, Gupta VK, Yaffe B, Modi S, Roy P, Sethi V, Lavania SP, Vickers SM, Dudeja V, Banerjee S, et al. Pre-clinical analysis of Minnelide as a remedy for acute myeloid leukemia. J Transl Med. 2019;17:163.
Jia G, Jiang X, Li Z, Ding X, Lei L, Xu S, Gao N. Decoding the mechanism of Shen Qi Sha Bai Decoction in treating Acute myeloid leukemia primarily based on Community Pharmacology and Molecular Docking. Entrance Cell Dev Biol. 2021;9:796757.
Lian Y, Wang X, Guo P, Li Y, Raza F, Su J, Qiu M. Erythrocyte membrane-coated Arsenic Trioxide-Loaded Sodium Alginate Nanoparticles for Tumor Remedy. Pharmaceutics 2019, 12.
Peng Y, Zhao Z, Liu T, Li X, Hu X, Wei X, Zhang X, Tan W. Good Human-Serum-Albumin-As(2) O(3) Nanodrug with Self-Amplified Folate receptor-targeting potential for continual myeloid leukemia therapy. Angew Chem Int Ed Engl. 2017;56:10845–9.
Su C, Liu Y, He Y, Gu J. Analytical strategies for investigating in vivo destiny of nanoliposomes: a evaluate. J Pharm Anal. 2018;8:219–25.
Li YJ, Hu XB, Lu XL, Liao DH, Tang TT, Wu JY, Xiang DX. Nanoemulsion-based supply system for enhanced oral bioavailability and caco-2 cell monolayers permeability of berberine hydrochloride. Drug Deliv. 2017;24:1868–73.
Hemeg HA. Nanomaterials for various antibacterial remedy. Int J Nanomedicine. 2017;12:8211–25.
Guo D, Wu C, Track W, Jiang H, Wang X, Chen B. Impact of colloidal gold nanoparticles on cell interface and their enhanced intracellular uptake of arsenic trioxide in leukemia most cancers cells. J Nanosci Nanotechnol. 2009;9:4611–7.
Silverman JA, Reynolds L, Deitcher SR. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. J Clin Pharmacol. 2013;53:1139–45.
Finlayson M. Modulation of CD44 exercise by A6-Peptide. Entrance Immunol. 2015;6:135.
Gu W, Liu T, Fan D, Zhang J, Xia Y, Meng F, Xu Y, Cornelissen J, Liu Z, Zhong Z. A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a sensible and particular therapy for CD44 + acute myeloid leukemia. J Management Launch. 2021;329:706–16.
Zhang X, Chen H, Huang X, Xu H, Li Y, Yuan H, Yu J, Gao Y. Single-cell transcriptomics profiling the compatibility mechanism of as(2)O(3)-indigo naturalis system primarily based on bone marrow stroma cells. Biomed Pharmacother. 2022;151:113182.
Pi Ok, Markelova E, Zhang P, Van Cappellen P. Arsenic oxidation by Flavin-Derived reactive species beneath oxic and anoxic situations: oxidant formation and pH dependence. Environ Sci Technol. 2019;53:10897–905.
Fan J, He Q, Wang Z, Huang W, Cai Z. Self-assembled Nanocomplex for Co-Supply of Arsenic-Retinoic Acid Prodrug into Acute promyelocytic leukemia cells. J Biomed Nanotechnol. 2018;14:1052–65.
Liu X, Meng H. Consideration for the scale-up manufacture of nanotherapeutics—A crucial step for expertise switch. View. 2021;2:20200190.
Paliwal R, Babu RJ, Palakurthi S. Nanomedicine scale-up applied sciences: feasibilities and challenges. AAPS PharmSciTech. 2014;15:1527–34.
Metselaar JM, Lammers T. Challenges in nanomedicine scientific translation. Drug Deliv Transl Res. 2020;10:721–5.
Younis MA, Tawfeek HM, Abdellatif AAH, Abdel-Aleem JA, Harashima H. Medical translation of nanomedicines: Challenges, alternatives, and keys. Adv Drug Deliv Rev. 2022;181:114083.
Foulkes R, Man E, Thind J, Yeung S, Pleasure A, Hoskins C. The regulation of nanomaterials and nanomedicines for scientific utility: present and future views. Biomaterials Sci. 2020;8:4653–64.
Zheng C, Li M, Ding J. Challenges and Alternatives of Nanomedicines in scientific translation. BIO Integr. 2021;2:57–60.
Nirachonkul W, Ogonoki S, Thumvijit T, Chiampanichayakul S, Panyajai P, Anuchapreeda S, Tima S, Chiampanichayakul S. CD123-Focused Nano-Curcumin Molecule enhances cytotoxic efficacy in leukemic stem cells. Nanomaterials (Basel). 2021;11(11):2974.
Zong H, Sen S, Zhang G, Mu C, Albayati ZF, Gorenstein DG, Liu X, Ferrari M, Crooks PA, Roboz GJ, et al. In vivo focusing on of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow area of interest. Leukemia. 2016;30:1582–6.
Tan W, Li Y, Chen M, Wang Y. Berberine hydrochloride: anticancer exercise and nanoparticulate supply system. Int J Nanomedicine. 2011;6:1773–7.
Chen B, Liang Y, Wu W, Cheng J, Xia G, Gao F, Ding J, Gao C, Shao Z, Li G, et al. Synergistic impact of magnetic nanoparticles of Fe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine. 2009;4:251–9.
Zhang Ok, Lin H, Mao J, Luo X, Wei R, Su Z, Zhou B, Li D, Gao J, Shan H. An extracellular pH-driven focused multifunctional manganese arsenite supply system for tumor imaging and remedy. Biomater Sci. 2019;7:2480–90.
Chen M, Qiao Y, Cao J, Ta L, Ci T, Ke X. Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia. J Nanobiotechnol. 2022;20:273.
Liang YQ, Chen BA, Wu WW, Gao F, Xia GH, Shao ZY, et al. Results of magnetic nanoparticle of Fe3O4 on apoptosis induced by gambogic acid in U937 leukemia cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:67–73.
